A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)
- Registration Number
- NCT02024789
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This multi-center, randomized, double-blind, 3-arm, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RG1662 in adults and adolescents with Down syndrome. Subjects will be randomized to receive RG1662 either at low or high dose or placebo orally twice daily for 26 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 173
- Individuals aged 12-30 years of age inclusive
- Clinical diagnosis of Down syndrome (trisomy 21) confirmed by chromosomal analysis (karyotyping)
- Males, or non-pregnant, non-lactating females. For females of childbearing potential, strict contraceptive prevention is required.
- Body-mass Index (BMI) 18-42 and 15-30 kg/m2 inclusive for adults and adolescents respectively
- Ability to complete the Clinical Evaluation of Language Fundamentals (CELF)-preschool 2 word classes task
- Subjects must have a parent, or other reliable caregiver who agrees to accompany the subject to all clinic visits, provide information about the subject as required by the protocol, and ensure compliance with the medication schedule
- Study participants must have sufficient language, vision and hearing to participate in study evaluations, as judged clinically by investigator
- Subjects with a current DSM 5 diagnosis of any primary psychiatric diagnosis (including ASD or MDD)
- Subjects with a history of infantile spasms, of West syndrome, Lennox-Gastaut syndrome, Early Infantile Epileptic Encephalopathy or any treatment-refractory epilepsy associated with cognitive or developmental regression, of severe head trauma or CNS infections (e.g. meningitis)
- Subjects with a known or suspected clinical seizure event of any type within 24 months prior to screening
- Clinically relevant ECG abnormalities at screening or baseline; QTcF above 450 ms; personal or family history (first degree relatives) of congenital long QT syndrome
- Inadequate renal or hepatic function
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo - RG1662 120 mg bid RG1662 - RG1662 240 mg bid RG1662 -
- Primary Outcome Measures
Name Time Method Cognition as assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) sub-tests 26 weeks Adaptive behavior as assessed by the Vineland Adaptive Behavior Scales-II (VABS-II) standard scores 26 weeks Clinical global impression as assessed by Clinician Rated Global Improvement (CGI-I) scale 26 weeks
- Secondary Outcome Measures
Name Time Method Abnormal ECG changes in adolescents as compared to baseline from baseline to Week 26 Safety: Incidence of adverse events approximately 32 weeks RG1662 plasma concentrations 26 weeks Incidence of abnormal blood pressure 26 weeks Incidence of abnormal ECG changes 26 weeks
Trial Locations
- Locations (37)
Univ of CA San Diego; Neurosciences Comp.Alzheimer's
🇺🇸La Jolla, California, United States
University of California DAVIS Medical Center; M.I.N.D. Institute, Section of Developmental Behavior
🇺🇸Sacramento, California, United States
Emory University School of Medicine; Department of Human Genetics & Pediatrics
🇺🇸Decatur, Georgia, United States
Rush University Medical Center
🇺🇸Chicago, Illinois, United States
Johns Hopkins Hospital.
🇺🇸Baltimore, Maryland, United States
Massachusette General Hospital; Medical Genetics
🇺🇸Boston, Massachusetts, United States
Duke Clin Rsch Institute
🇺🇸Durham, North Carolina, United States
University of Utah School of Medicine; Department of Pediatrics
🇺🇸Salt Lake City, Utah, United States
University of Wisconsin Madison, Waisman Center
🇺🇸Madison, Wisconsin, United States
FLENI
🇦🇷Caba, Argentina
Scroll for more (27 remaining)Univ of CA San Diego; Neurosciences Comp.Alzheimer's🇺🇸La Jolla, California, United States